HROW241220P25000
- 1.70
- 0.000.00%
Harrow Newsroom
Express News | Harrow Inc - Melt-300 Shows Statistical Superiority Over Midazolam and Placebo
Express News | Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for Melt-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Melt Pharmaceuticals Reports Positive Phase 3 Topline Efficacy Results for MELT-300, Its Lead Product Candidate for Opioid-Free, Sublingual Procedural Sedation in Patients Undergoing Cataract Surgery
Lake Street Initiates Harrow(HROW.US) With Buy Rating, Announces Target Price $55
Harrow Health's Strategic Transformation and Growth Potential Underscore Buy Rating
US Manufacturing Index Rises To 43, Highest Since 2020
Harrow Announces Participation in Upcoming Investor Conferences
Harrow Inc. Reports Strong Q3 2024 Growth
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Harrow, Inc. (HROW) Q3 2024 Earnings Call Transcript Summary
Harrow Down Nearly 13%, on Pace for Largest Percent Decrease Since November 2023 -- Data Talk
Express News | Harrow Shares Down 18% After Q3 Revenue Misses Estimate
Craig-Hallum Maintains Harrow(HROW.US) With Buy Rating
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $55
Wall Street Set to Open Flat Thursday; Initial Jobless Claims Lower Than Forecast
B.Riley Financial Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $73
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Top Premarket Decliners
Harrow Health: Strong Growth Prospects Amid Market Overreaction
10-Q: Q3 2024 Earnings Report